{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T17:54:14Z","timestamp":1777917254797,"version":"3.51.4"},"reference-count":79,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[1993,2,1]],"date-time":"1993-02-01T00:00:00Z","timestamp":728524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Decis Making"],"published-print":{"date-parts":[[1993,2]]},"abstract":"<jats:p>This paper examines the economic attractiveness of universal vaccination of infants with hepatitis B virus (HBV) vaccine by calculating the incremental cost-effectiveness of this strategy when compared with the currently recommended strategy of screening all pregnant women and vaccinating only infants born to HBsAg+ mothers. A decision-analytic model involving a Markov process to model the long-term sequelae of HBV infection was constructed to estimate the expected costs and life expectancies for a cohort of newborns under two strategies: the current screening policy (SELECTIVE), which involves active and passive vac cination of infants born to carrier mothers, and a policy that combines the current screening strategy (including active and passive vaccination of infants born to carriers) with active vaccination alone for children of non-carriers (UNIVERSAL). A hypothetical cohort of children born in either Canada or the United States in 1991 was examined. Cost estimates were derived for Ontario. From a societal perspective, the incremental cost required to achieve one extra life year was found to be $30,347, comparable to the cost-effectivenesses of other health care strategies commonly used in North America. The result is sensitive to the duration of vaccine effectiveness and particularly to the price of the vaccine. Universal vaccination results in net cost saving at a vaccine price of approximately $7 per dose, from a societal perspective. It is concluded that universal vaccination against HBV in infancy is economically attractive, comparable in cost-effectiveness to existing health care interven tions. Lower vaccine prices would substantially improve the attractiveness of such a program. Implementation of universal vaccination should be considered in North America, contingent on vaccine price reduction. A monitoring program to ensure the long-term efficacy of the vaccine should be part of such a program. Key words: vaccination; hepatitis B; cost-effec tiveness; prevention; chronic hepatitis. (Med Decis Making 1993;13:4-20)<\/jats:p>","DOI":"10.1177\/0272989x9301300103","type":"journal-article","created":{"date-parts":[[2007,3,18]],"date-time":"2007-03-18T00:13:15Z","timestamp":1174176795000},"page":"4-20","source":"Crossref","is-referenced-by-count":52,"title":["Should Canada and the United States Universally Vaccinate Infants against Hepatitis B?"],"prefix":"10.1177","volume":"13","author":[{"given":"Murray","family":"Krahn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allan S.","family":"Detsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[1993,2,1]]},"reference":[{"key":"atypb1","unstructured":"Maynard JE, Kane MA, Alter MJ, Hadler SC Control of hepatitis B by immunization: global perspectives In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988 ;967-9."},{"key":"atypb2","unstructured":"Szmuness W., Harley E., Ikram H., et al. Sociodemographic aspects of the epidemiology of hepatitis B In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis. Philadelphia: Franklin Institute Press, 1978;17-21."},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J"},{"key":"atypb4","unstructured":"Beasley RP, Hwang LY Epidemiology of hepatocellular carcinoma In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune & Stratton, 1984;209-24."},{"key":"atypb5","unstructured":"Centers for Disease Control. Hepatitis surveillance report no. 51 Atlanta: United States Department of Health and Human Services, Public Health Service , 1987;19-20."},{"key":"atypb6","first-page":"353","volume":"36","author":"Centers for Disease Control.","year":"1987","journal-title":"MMWR."},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198911093211910"},{"key":"atypb8","first-page":"349","volume":"91","author":"Tolsma DD","year":"1976","journal-title":"Public Health Rep."},{"key":"atypb9","first-page":"28","volume":"37","author":"Centers for Disease Control.","year":"1988","journal-title":"MMWR."},{"key":"atypb10","first-page":"303","volume":"137","author":"National Advisory Committee on Immunization.","year":"1987","journal-title":"Can Med Assoc J."},{"key":"atypb11","first-page":"341","volume":"37","author":"Advisory Committee on Immunization Practices.","year":"1988","journal-title":"MMWR."},{"key":"atypb12","series-title":"Am J Med.","volume-title":"Hepatitis B infection in the United States: recent trends and strategies for control","author":"Kane MA","year":"1989"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90522-6"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03440090052025"},{"key":"atypb15","volume-title":"Medical decision making","author":"Sox HC","year":"1988"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X8300300403"},{"key":"atypb17","volume-title":"Employment earnings and hours","author":"Statistics Canada."},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-113-2-147"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462300008461"},{"key":"atypb20","first-page":"473","volume":"146","author":"Laupacis A.","year":"1992","journal-title":"Can Med Assoc J."},{"key":"atypb21","first-page":"389","volume":"140","author":"Goel V.","year":"1989","journal-title":"Can Med Assoc J."},{"key":"atypb22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/131.2.111"},{"key":"atypb23","unstructured":"Dodd RY, Nath N., Bastiaans MJ, et al. Hepatitis associated markers in the American Red Cross donor population: 10 years experience In: Szmuness W, Alter HJ, Maynard JE, eds. Viral hepatitis : 1981 International Symposium. Philadelphia: Franklin Institute Press; 1981:145-55."},{"key":"atypb24","first-page":"14","author":"Sekla LH","year":"1988","journal-title":"Canada Diseases Weekly Rep."},{"key":"atypb25","first-page":"15","author":"Waters JR","year":"1989","journal-title":"Canada Diseases Weekly Rep."},{"key":"atypb26","first-page":"897","volume":"134","author":"Delage G.","year":"1986","journal-title":"Can Med Assoc J."},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197504102921503"},{"key":"atypb28","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890030310"},{"key":"atypb29","unstructured":"Nishioka K. Predominant mode of transmission of hepatitis B virus: perinatal transmission Asia In: Vyas GN, Dienstag JL, Hoofnagle JH, eds. Viral hepatitis and liver disease. New York: Grune and Stratton, 1984;423-32."},{"key":"atypb30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1542\/peds.76.5.713","volume":"76","author":"Xu Z.","year":"1985","journal-title":"Pediatrics."},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90624-4"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)90003-2"},{"key":"atypb33","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1988.03410150079034"},{"key":"atypb34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1989.03420220092033"},{"key":"atypb35","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840070525"},{"key":"atypb36","first-page":"139","volume":"63","author":"Meheus A.","year":"1987","journal-title":"Postgrad Med J."},{"key":"atypb37","first-page":"1014","author":"Chung WK","year":"1988","journal-title":"Viral hepatitis and liver disease."},{"key":"atypb38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90977-1"},{"key":"atypb39","series-title":"Hepatitis B.","volume-title":"Hepatitis B surface antigen and antibody (HBsAg\/ HBsAb)","author":"Holland P.","year":"1985"},{"key":"atypb40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1542\/peds.70.4.557","volume":"70","author":"Sinatra FR","year":"1982","journal-title":"Pediatrics."},{"key":"atypb41","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1542\/peds.72.2.176","volume":"72","author":"Delaplane D.","year":"1983","journal-title":"Pediatrics."},{"key":"atypb42","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(81)90072-X"},{"key":"atypb43","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840030201"},{"key":"atypb44","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/127.1.17"},{"key":"atypb45","first-page":"404","volume":"123","author":"Schober A.","year":"1972","journal-title":"Am J Dis Child"},{"key":"atypb46","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a114496"},{"key":"atypb47","volume-title":"Notifiable diseases annual summary report","author":"Statistics Canada."},{"key":"atypb48","volume":"87","author":"McQuillan GM","year":"1989","journal-title":"Am J Med."},{"key":"atypb49","unstructured":"Statistics Canada. Vital statistics, Vol. 3, Deaths Hull, Quebec: Ministry of Supply and Services, Canada; 1988: Cat. 84-206."},{"key":"atypb50","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080629"},{"key":"atypb51","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198607243150401"},{"key":"atypb52","unstructured":"West DJ, Brown KR, Miller WJ, et al. Persistence of anti-HBs in recipients of a yeast recombinant hepatitis B vaccine In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988;1043-6."},{"key":"atypb53","unstructured":"Gibas A., Watkins E., Hinkle C., Dienstag J. Long term persistence of protective antibody after hepatitis B vaccination of healthy adults In: Zuckerman AJ, ed. Viral hepatitis and liver disease. New York: Alan R. Liss, 1988;998-1001."},{"key":"atypb54","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-2-185"},{"key":"atypb55","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a112370"},{"key":"atypb56","first-page":"388","volume":"2","author":"Beasley RP","year":"1979","journal-title":"Lancet."},{"key":"atypb57","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890220102"},{"key":"atypb58","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.4.599"},{"key":"atypb59","doi-asserted-by":"crossref","unstructured":"Beasley RP, Hwang LY, Lin CC, et al. Incidence of hepatitis B infections in preschool children in Taiwan. J Infect Dis. 1982;146:198-204.","DOI":"10.1093\/infdis\/146.2.198"},{"key":"atypb60","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010093031501"},{"key":"atypb61","unstructured":"Hoofnagle JH, Seeff LB, Bales ZB, et al. Serologic responses in hepatitis B In: Vyas GN, Cohen SN, Schmid R, eds. Viral hepatitis. Philadelphia: Franklin Institute Press; 1978:219-42."},{"key":"atypb62","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/pgmj.63.746.1097","volume":"63","author":"Sherlock S.","year":"1987","journal-title":"Postgrad Med J."},{"key":"atypb63","first-page":"788","volume":"101","author":"Pearce G.","year":"1988","journal-title":"NZ Med J."},{"key":"atypb64","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113532"},{"key":"atypb65","doi-asserted-by":"publisher","DOI":"10.1007\/BF01638719"},{"key":"atypb66","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197111182852101"},{"key":"atypb67","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(16)31984-8"},{"key":"atypb68","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1990.00390170087019"},{"key":"atypb69","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)90585-7"},{"key":"atypb70","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/151.4.604"},{"key":"atypb71","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-197901000-00002"},{"key":"atypb72","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080310"},{"key":"atypb73","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(82)80294-1"},{"key":"atypb74","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/146.2.205"},{"key":"atypb75","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-744"},{"key":"atypb76","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-101-5-613"},{"key":"atypb77","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910250609"},{"key":"atypb78","doi-asserted-by":"crossref","unstructured":"Oberfield RA, Steele G., Golan J., Sherman D. Liver cancer. Ca 1989;39:206-18.","DOI":"10.3322\/canjclin.39.4.206"},{"key":"atypb79","first-page":"3","volume":"39","author":"Silverberg E.","year":"1989","journal-title":"Ca."}],"container-title":["Medical Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X9301300103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0272989X9301300103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:08:47Z","timestamp":1777658927000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0272989X9301300103"}},"subtitle":["A Cost - Effectiveness Analysis"],"short-title":[],"issued":{"date-parts":[[1993,2]]},"references-count":79,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1993,2]]}},"alternative-id":["10.1177\/0272989X9301300103"],"URL":"https:\/\/doi.org\/10.1177\/0272989x9301300103","relation":{},"ISSN":["0272-989X","1552-681X"],"issn-type":[{"value":"0272-989X","type":"print"},{"value":"1552-681X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1993,2]]}}}